Non-surgical management of spinal cord injury

Expert Opinion on Investigational Drugs
Jeffrey J LegosWilliam F Young

Abstract

Spinal cord injury remains a devastating neurological condition with limited therapeutic opportunities. Since decompressive surgery and high-dose methylprednisolone have limited utility for most patients, spinal cord injury clearly represents a major medical challenge. Experimental evidence has suggested that secondary cellular injury processes may be a realistic target for therapeutic intervention with the goal of inhibiting the progression of detrimental changes that normally follows traumatic injury to the cord. Preventing or reducing this delayed cellular injury may alone improve neurological recovery or facilitate future regenerative approaches to the injured cord. This review summarises recent advances in the development of pharmacological agents targeting the acute phase of spinal cord injury as well as potential strategies to facilitate regeneration of the spinal cord.

References

Dec 1, 1975·Journal of Neurosurgery·J S HeidenT Kurze
Jan 1, 1992·Journal of Neurotrauma·D K Anderson
Jan 1, 1992·Journal of Neurosurgery·E D Hall
May 1, 1995·Surgical Neurology·S S HaghighiJ J Oro
Apr 1, 1994·Journal of Neurosurgical Anesthesiology·W F YoungR F Tuma
Jun 1, 1993·Annals of Emergency Medicine·E D Hall
Jun 1, 1993·Annals of Emergency Medicine·D K Anderson, E D Hall
Jan 31, 1996·Neuroreport·J M StutzmannC Gross
Sep 1, 1996·Journal of Neuroimmunology·C X WangJ Gybels
Jan 20, 1997·The Journal of Comparative Neurology·P G PopovichB T Stokes
Feb 7, 1997·Cell·S J MorrisonD J Anderson
Feb 1, 1997·The Journal of Trauma·S J GerndtS M Papadopoulos
Mar 4, 1997·Proceedings of the National Academy of Sciences of the United States of America·J P SteinerP D Suzdak
Aug 1, 1997·Neuroscience·Y TaokaK Takatsuki
Jul 11, 1997·Brain Research·I Klusman, M E Schwab
Feb 10, 1998·The Journal of Comparative Neurology·M ShibayamaA Tessler
Mar 14, 1998·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·M EndresM A Moskowitz
May 13, 1998·Neurologic Clinics·D W Marion
Jun 6, 1998·Experimental Neurology·S L CarlsonL Dossett
Oct 14, 1998·Progress in Neurobiology·Y Taoka, K Okajima
Oct 20, 1998·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·K FinkM A Moskowitz
Oct 24, 1998·The European Journal of Neuroscience·E J BradburyS B McMahon
Dec 2, 1998·Journal of Neurosurgery·E EmeryA D Levi

❮ Previous
Next ❯

Citations

Dec 24, 2004·Archives of Orthopaedic and Trauma Surgery·K-S DelankP Eysel
Jul 16, 2014·Experimental Neurology·Jason R PlemelDavid P Stirling
Apr 15, 2008·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Hung-Chuan PanMaw-Sheng Lee
Jan 1, 2008·Journal of Land Use Science·V YadavG P Malanson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.